Todos Med Ltd (TOMDF)

[JoeForkeyBolo]

There is a disclaimer at the end of the article, but it doesn't provide any info on the author's ownership status.

Disclosure: Insider Financial and its owners do not have a position in the stocks posted and have posted this article for free without editorial input. This article was written by a guest contributor and solely reflects his opinions.

There is another disclaimer for the site that goes into much greater detail at this link:
https://insiderfinancial.com/disclaimer/

I'm not trying to convince you of anything. It makes no difference to me if you invest or not, if you pass on this article or not. Maybe he responds, maybe he doesn't. While I agree we don't know this person and might be suspect of his response (if any), I would assume if he does state he is a shareholder, then why would that be a lie? Yes, it could indicate bias in the article, but being a shareholder doesn't automatically infer bias. The article seems well researched with plenty of links to the companies mentioned and is clearly the author's opinion. I believe the article gives a fair account of current events and there is enough uncertainty stated to indicate this is definitely NOT a sure thing for Todos, or even for Pfizer. No one knows with any certainty how this story will unfold.

To each his own. Every one of us has motives. My motivation is to make money with this investment, but I won't go as far as lying about the company, nor will I pump the stock to get a better price if I'm looking to exit. I continue to tell those who read my posts to invest only what you can afford to lose in the penny stock realm. This is still a high risk investment. Anyone who reads this article and decides they can get rich quick by investing all of their money in Todos is a gambler and not an investor and may live to regret that decision. There's still a good deal of uncertainty here, but in my opinion things are looking better than at any time in the past regarding the company's potential, with is not reflected in the share price. Dilution with fundraising has hurt us there. Let's see what the financial update reveals.